Bìol. Tvarin, 2017, volume 19, issue 3, pp. 55–68


V. M. Oksamytnyi

This email address is being protected from spambots. You need JavaScript enabled to view it.

State scientific institution “State Centre of Innovation Biotechnologies”,
30 Donetska str. Kyiv, 03151, Ukraine, This email address is being protected from spambots. You need JavaScript enabled to view it.

The information about the use of interferons in veterinary medicine in terms of historical and technological development of science is provided. The research centers in the world, the former Soviet Union and Ukraine, which first began to study the protective effect of interferon and develop drugs based on it are mentioned. The difficulties in the creation of the first preparations of interferons and ways to overcome them are specified. The examples of the successful application of the first natural interferon drugs for the treatment of diseases in different livestock industries: cattle, swine, sheep, poultry and small animals are given. The studies on the search for highly active inducers of endogenous interferon and their use with a therapeutic purpose are mentioned. The achievements of Ukrainian scientists in the study, development and use of therapeutic and prophylactic preparations on the basis of native interferons are described. The practical results of development and introduction of domestic products is highly modified interferons for the treatment and prevention of infectious diseases of farm animals are cited.

It is indicated that the introduction of genetic engineering methods for the production of recombinant interferons has made it possible to significantly reduce the cost of manufacturing such drugs and to use recombinant interferons of some species of animals and humans for the treatment of animal diseases of other species.

It was noted that the discovery of new types of interferons, in particular omega, ipsilon, kappa, delta, tau and lambda in recent years contributed to their chosen application with maximum efficiency for treating many diseases in different animal species.

The results of clinical studies of various interferon preparations on the most common types of agricultural and domestic animals are presented. The disclosure of molecular mechanisms of interferon action, including at the gene level, allowed to apply new approaches to the use of protective possibilities of interferon therapy.

These data indicate the prospects for studying, developing and using interferon preparations for the prevention and treatment of diseases of farm animals.


  1. Abolhassani M., Jacobsen K.L. Purification of an acid-stable bovine leukocyte interferon.Vet. Immunol. Iimmunopathol., 1991, vol. 29, no. 1, pp. 171–181. https://doi.org/10.1016/0165-2427(91)90062-H
  2. Ahl R., Rump A.Assay of bovine interferons in cultures of the porcine cell line IB-RS-2.Infect. Immun., 1976, vol. 14, no. 3, pp. 603–606.
  3. Akai M., Hobo S., Wada S. Effect of Low-Dose Human Interferon-alpha on Shipping Fever of Thoroughbred Racehorses. J. Equine Sci., 2008, vol. 19, no. 4, pp. 91–95. https://doi.org/10.1294/jes.19.91
  4. Akiyama K., Sugii S., Hirota Y. A clinical trial of recombinant bovine interferon alpha 1 for the control of bovine respiratory disease in calves. J. Vet. Med. Sci., 1993, vol. 55, no. 3, pp. 449–452. https://doi.org/10.1292/jvms.55.449
  5. Ank N., West H., Bartholdy C., Eriksson K., Thomsen A.R., Paludan S.R. Lambda interferon (IFN-λ), a type III IFN, is induced by viruses and displays potent antiviral activity against select virus infections in vivo. J. Virol., 2006, vol. 80, no. 9, pp. 4501–4509. https://doi.org/10.1128/JVI.80.9.4501-4509.2006
  6. Aryefyev V.L., Oksamytnyi V.M. Use of the drug “Bovivireks” for the prevention of acute respiratory infections in calves. Proc. Intern. Sci. Pract. Symp. “Problems of infectious pathology of animals”, Krym, Novyi Svit, 2001. (in Ukrainian)
  7. Babiuk L. A., Lawman M. J., Gifford G. A. Use of recombinant bovine alpha 1 interferon in reducing respiratory disease induced by bovine herpesvirus type 1. Antimicrob. Agents Chemother., 1987, vol. 31, no.5, pp. 752–757. https://doi.org/10.1128/AAC.31.5.752
  8. Babiuk L. A., Rouse B. T. Bovine type II interferon: activity in heterologous cells. Intervirology, 1977, vol. 8, no. 4, pp. 250–256. https://doi.org/10.1159/000148900
  9. Boudinot P., Langevin C., Secombes C. J., Levraud J.-P. The Peculiar Characteristics of Fish Type I Interferons. Viruses, 2016, vol. 8, no. 11, p. 298. https://doi.org/10.3390/v8110298
  10. Bukata L. A., Nosik N. N., Fomina A. N. Comparative antiviral and interferonogenic activity of natural and synthetic interferon inducers in vitro and in vivo. Antibiotics, 1979, no. 6, pp. 444–448. (in Russian)
  11. Carlotti D. N., Boulet M., Ducret J., Machicote G., Jasmin P., Rème C.A., Albouy M. The use of recombinant omega interferon therapy in canine atopic dermatitis: a double-blind controlled study. Vet. Dermatol., 2009, vol. 20, no. 5–6, pp. 405–411. https://doi.org/10.1111/j.1365-3164.2009.00848.x
  12. Chang C. J., Jenssen I., Robertsen B. Protection of Atlantic Salmon Against Salmonid Alphavirus Infection by Type I Interferons IFNa, IFNb and IFNc. Fish Shellfish Immunol., vol. 57, pp. 35–40. https://doi.org/10.1016/j.fsi.2016.08.020
  13. Chang C. J., Robertsen C., Sun B., Robertsen B. Protection of Atlantic Salmon Against Virus Infection by Intramuscular Injection of IFNc Expression Plasmid. Vaccine, vol. 32, no. 36, pp. 4695–4702. https://doi.org/10.1016/j.vaccine.2014.05.059
  14. Charley B., McCullough K., Martinod S. Antiviral and antigenic properties of recombinant porcine interferon gamma. Vet. Immunol. Immunophathol., 1988, vol. 19, no. 2, pp. 95–103. https://doi.org/10.1016/0165-2427(88)90001-3
  15. Chen S., Zhang W., Zhou Q., Wang A., Sun L., Wang M., Jia R., Zhu D., Liu M., Sun K., Yang Q., Wu Y., Chen X., Cheng A. Cross-species antiviral activity of goose interferon lambda against duck plague virus is related to its positive self-regulatory feedback loop. J. Gen. Virol., 2017, vol. 98, no. 6, pp. 1455–1466. https://doi.org/10.1099/jgv.0.000788
  16. Cummins J. M., Gawthrop J., Hutcheson D. P., Cummins M. J., Zeck D. The effect of low dose oral human interferon alpha therapy on diarrhea in veal calves. Arch. Immunol. Ther. Exp., 1993, vol. 41, no. 3–4, pp. 199–203.
  17. Cummins J. M., Guthrie D., Hutcheson D. P., Krakowka S., Rosenquist B. D. Natural human interferon-alpha administered orally as a treatment of bovine respiratory disease complex. J. Interferon Cytokine Res., 1999, vol. 19, no. 8, pp. 907–910. https://doi.org/10.1089/107999099313442
  18. Cummins J. M., Hutcheson D. P. Oral therapy with human interferon alpha in calves experimentally injected with infectious bovine rhinotracheitis virus. Arch. Immunol. Ther. Exp., 1993, vol. 41, no. 3–4, pp. 193–197.
  19. Cummins J. M., Mock R. E., Shive B. W., Krakowka S., Richards A. B., Hutcheson D. P. Oral treatment of transmissible gastroenteritis with natural human interferon alpha: a field study. Vet. Immunol. Immunopathol., 1995, vol. 45, no. 3–4, pp. 355–360. https://doi.org/10.1016/0165-2427(94)05351-R
  20. Cummins J. M., Tompkins M. B., Olsen R. G., Tompkins W. A., Lewis M. G. Oral use of human alpha interferon in cats. J. Biol. Response Mod., 1988, vol. 7, no. 5, pp. 513–523.
  21. Czarniecki C. W., Hamilton E. B., Fennie C. W. In vitro biological activities of Escherichia coli derived bovine interferon alfa, beta, gamma. J. Interferon Res., 1986, vol. 6, no. 1, pp. 29–37. https://doi.org/10.1089/jir.1986.6.29
  22. De Mari K., Maynard L., Eun H. M., Lebreux B. Treatment of canine parvoviral enteritis with interferon-omega in a placebocontrolled field trial. Vet. Rec., 2003, vol. 152, no. 4, pp. 105–108. https://doi.org/10.1136/vr.152.4.105
  23. De Mari K., Maynard L., Sanquer A., Lebreux B., Eun H. M. Therapeutic effects of recombinant feline interferon-omega on feline leukaemia virus (FeLV)-infected and FeLV/feline immunodeficiency virus (FIV)-coinfected symptomatic cats. J. Vet. Inter. Med., 2004, vol. 18, no. 4, pp. 477–482. https://doi.org/10.1892/0891-6640(2004)18<477:TEORFI>2.0.CO;2
  24. Dec M., Puchalski A. Use of oromucosally administered interferon-alpha in the prevention and treatment of animal diseases. Polish J. Vet. Sci., 2007, vol. 11, no. 2, pp. 175–186.
  25. Derbyshire J. B. The interferon sensitivity of selected porcine viruses. Canad. J. Veter. Res., 1989, vol. 53, no. 1, pp. 52–55.
  26. Devos R., Cheroutre H., Taya Y., Degrave W., Van Heuverswyn H., Fiers W. Molecular cloning of human immune interferon cDNA and its expression in eukaryotic cells. Nucleic Acids Res., 1982, vol. 10, no. 8, pp. 2487–2501. https://doi.org/10.1093/nar/10.8.2487
  27. Dias C. C. A., Moraes M. P., Segundo F. D. S, de los Santos T., Grubman M. J. Porcine type I interferon rapidly protects swine. J. Interferon Cytokine Res., 2011, vol. 31, no. 2, pp. 227–236. https://doi.org/10.1089/jir.2010.0055
  28. Díaz-San Segundo F., Weiss M., Perez-Martín E., Koster M. J., Zhu J., Grubman M. J., de los Santos T. Antiviral activity of bovine type III interferon against foot-and-mouth disease virus. Virology, 2011, vol.413, no. 2, pp. 283–292. https://doi.org/10.1016/j.virol.2011.02.023
  29. Doménech A., Miró G., Collado V. M., Ballesteros N., Sanjosé L., Escolar E., Martin S., Gomez-Lucia E. Use of recombinant interferon omega in feline retrovirosis: from theory to practice. Vet. Immun. Immunopath., 2011, vol. 143, no. 3–4, pp. 301–306. https://doi.org/10.1016/j.vetimm.2011.06.008
  30. Elizarova E. A., Velikanov V. I. The efficacy of Feliferon for calicivirus infection of cats. VetPharma, 2016, no. 4, pp. 38–41. (in Russian)
  1. European public assessment report (EPAR). Virbagen Omega. EMEA/V/C/061. EMEA, 2007.
  2. Fan W., Xu L., Ren L., Qu H., Li J., Liang J., Liu W., Yang L., Luo T. Functional Characterization of Canine Interferon-Lambda.J. Interferon Cytokine Res., 2014, vol. 34, no. 11, pp. 848–857. https://doi.org/10.1089/jir.2014.0009
  3. Feliferon — the first Russian drug of a cat interferon. VetPharma, 2015, no. 2, pp. 3–4. (in Russian)
  1. Forman M. S., Adams E. W., Vanderpool E. A., Turner W. Induction of acid-stable canine interferon in vivo and in vitro. Am. J. Vet. Res., 1979, vol. 40, no. 1, pp. 1440–1442.
  2. Fulton R. W., Burqe L. J. Susceptibility of feline herpes virus 1 and feline calicivirus to feline interferon and recombinant human leucocyte interferons. Antimicrob. Agents Chemother., 1985, vol. 28, no. 5, pp. 698–699. https://doi.org/10.1128/AAC.28.5.698
  3. Fulton R. W., Burqe L. J., McCraken J. S. Effect of recombinant DNA-derived bovine and human interferons on replication of bovine herpesvirus-1, parainfluenza-3, and respiratory syncytial viruses. Am. J. Vet. Res., 1986, vol. 47, no. 4, pp. 751–753.
  4. Fulton R. W., Downing M. M., Cummins J. M. Antiviral effects of bovine interferons on bovine respiratory tract viruses. J. Clin. Microbiol., 1984, vol. 19, no. 4, pp. 492–497.
  5. Fulton R. W., Teeter R. G., Cummins J. M., Georgiades J. A., Hutcheson D. P. The use of interferon modulates the negative effects of heat stress on poultry production. Arch. Immunol. Ther. Exp., 1993, vol. 41, no. 3–4, pp. 209–212.
  6. Georgiades J. Effect of low dose natural human interferon alpha given into the oral cavity on the recovery time and death loss in feedlot hospital pen cattle: a field study. Arch. Immunol. Ther. Exp., 1993, vol. 41, no. 3–4, pp. 205–207.
  7. Gifford G. E. Preparation and characterization of chicken interferon. Meth. Enzymol., 1981, vol. 78, pt. A, pp. 192–195. https://doi.org/10.1016/0076-6879(81)78117-5
  1. Gil S., Leal R. O., Duarte A., McGahie D., Sepúlveda N., Siborro I., Cravo J., Cartaxeiro C., Tavares L. M. Relevance of feline interferon omega for clinical improvement and reduction of concurrent viral excretion in retrovirus infected cats from a rescue shelter. Res.Vet. Sci., 2013, vol. 94, no. 3, pp. 753–763. https://doi.org/10.1016/j.rvsc.2012.09.025
  2. Gil S., Leal R. O., McGahie D., Sepúlveda N., Duarte A., Niza M. M. R. E., Tavares L. Oral Recombinant Feline Interferon-Omega as an alternative immune modulation therapy in FIV positive cats: Clinical and laboratory evaluation. Res. Vet. Sci., 2014, vol. 96, pp. 79–85. https://doi.org/10.1016/j.rvsc.2013.11.007
  3. Gillespie J., Scott F., Geissinger C., Schiff E. The prophylactic effects of E. coli derived bowine interferon alfa-1 on bovine diarrhoea virus disease in calver after intramuscular administration. J. Vet. Med., 1986, vol. 33, no. 1–10, pp. 771–776.
  4. Giotis E. S., Goodbourn S., Robey R. C., Skinner N. G., Skinner M. A., Tomlinson C. D. Chicken interferome: avian interferon-stimulated genes identified by microarray and RNA-seq of primary chick embryo fibroblasts treated with a chicken type I interferon (IFN-α). Vet. Res., 2016, vol. 47, no. 1, p. 75. https://doi.org/10.1186/s13567-016-0363-8
  5. Gresser I., Bandu M. T., Brouty-Boye D., Tovey M. Pronounced antiviral activity of human interferon on bovine and porcine cells. Nature, 1974, vol. 251, pp. 543–545. https://doi.org/10.1038/251543a0
  6. Ho M., Breinig M. C. Preparation and characterization of rabbit interferon. Meth. Enzymol., 1981, vol. 78, pt. A, pp. 131–138. https://doi.org/10.1016/0076-6879(81)78106-0
  7. Ishida T., Shibanai A., Tanaka S., Uchida K., Mochizuki M. Use of recombinant feline interferon and glucocorticoid in the treatment of feline infectious peritonitis. J. Feline Med. Surg., 2004, vol. 6, no. 2, pp. 107–109. https://doi.org/10.1016/j.jfms.2003.08.011
  8. Ishiwata K., Minagawa T., Kajimoto T. Clinical effects of the recombinant feline interferon-omega on experimental parvovirus infection in beagle dogs. J. Vet. Med. Sci., 1998, vol. 60, no. 8, pp. 911–917. https://doi.org/10.1292/jvms.60.911
  9. Jameson P., Essex M. Inhibition of feline leukemia virus replication by human leukocyte interferon. Antiviral Res., 1983, vol. 3, no. 2, pp. 115–120. https://doi.org/10.1016/0166-3542(83)90033-5
  10. Jang H., Ngunjiri J. M., Lee C.-W. Association between Interferon Response and Protective Efficacy of NS1-Truncated Mutants as Influenza Vaccine Candidates in Chickens. PLoS One, 2016, vol. 11, no. 6, e0156603. https://doi.org/10.1371/journal.pone.0156603
  11. Jarosinski K. W., Jia W., Sekellick M. J., Marcus P. I., Schat K. Cellular responses in chickens treated with IFN-α orally or inoculated with recombinant Marek’s disease virus expressing IFN-α. J. Interferon Cytokine Res., 2001, vol. 21, no. 5, pp. 287–296. https://doi.org/10.1089/107999001300177475
  12. Jiang H., Yang H., Kapczynski D. R. Chicken interferon alpha pretreatment reduces virus replication of pandemic H1N1 and H5N9 avian influenza viruses in lung cell cultures from different avian species. Virol. J., 2011, vol. 8, p. 447. https://doi.org/10.1186/1743-422X-8-447
  13. Karas O. Y., Kupchinsky L. G. A new generation of drugs interferon. Proc. Sci.-Pract. Symp. “Survival of young agricultural animals — a guarantee of livestock Ukraine”, Kharkiv, 1994, pp. 132–133. (in Ukrainian)
  14. Karpala A. J., Morris K. R., Broadway M. M, McWaters P. G., O’Neil T. E.,Goossens K. E., Lowenthal J. W., Bean A. G. Molecular cloning, expression, and characterization of chicken IFN-λ. J. Interferon Cytokine Res., 2008, vol. 28, no. 6, pp. 341–350. https://doi.org/10.1089/jir.2007.0117
  15. Khmylov A. Interferon-containing preparations. The end justifies the means. Svinovodstvo, 2015, no. 2, pp. 53–54. (in Russian)
  1. Kishko Ya. G., Ivanenko V. K. The perspective of interferon preparations using for prophylaxis and treatment of virus diseases in agricultural animals. Abstr. of 8th Intern. Congr. Virol., Berlin, 1990, p. 340.
  2. Klemann S. W., Li J. Z., Imakawa K., Cross J. C., Francis H., Roberts R. M. The production, purification, and bioactivity of recombinant bovine trophoblast protein-1 (bovine trophoblast interferon). Mol. Endocrinol., 1990, vol. 4, no. 10, pp. 1506–1514. https://doi.org/10.1210/mend-4-10-1506
  3. Kohara J., Nishikura Y., Konnai S., Tajima M., Onuma M. Effects of interferon-τ on cattle persistently infected with bovine viral diarrhea virus. Japanese J. Vet. Res., 2012, vol. 60, no. 2–3, pp. 63–70.
  1. Krakowka S., Cummins J. M., Ringler S. S. The effects of human interferoon-alpha upon in vitro canine immune responses. Vet. Immunol. Immunophathol., 1988, vol. 19, no. 3–4, pp. 185–196. https://doi.org/10.1016/0165-2427(88)90106-7
  2. Kugel D., Kochs G., Obojes K., Roth J., Kobinger G. P., Kobasa D., Haller O., Staeheli P., von Messling V. Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets. J. Virol., vol.83, no. 8, pp. 3843–3851. https://doi.org/10.1128/JVI.02453-08
  3. Lazarev O. P., Aryefyev V. L., Bilodid T. O., Oksamytnyi V. M., Scherban E. V. Treatment of acute infectious disease of young cattle with drug “Bovivireks”. Proc. of Intern. Sci. Pract. Symp. “Problems of infectious pathology of animals”, Krym, Novyi Svit, 2001. (in Ukrainian)
  4. Lazarev O. P., Spivak M. Ya., Oksamytnyi V. M., Karas O. Ya. Development of technology of industrial production of highly active interferons drugs in farm animals. Proc. of Sci.-Pract. Symp. “Survival of young agricultural animals — a guarantee of livestock Ukraine”, Kharkiv, 1994, pp. 130–132. (in Ukrainian)
  5. Lazarev O. P., Voloschenko U. V., Spivak M. Ya., Oksamytnyi V. M., Didenko N. Yu., Karas O. Ya., Kupchinsky L. G., Pischik P. P., Pushko N. P., Bilodid T. O., Scherban E. V., Sapeyko V. P. Biotechnology for industrial production and control of lymphokines drugs for farm animals. Proc. of Sci.-Pract. Symp. “Scientific support of agriculture of Ukraine in modern terms”, Bila Tserkva, 1995, pp. 83–84. (in Ukrainian)
  6. Leal R. O., Gil S., Duarte A., McGahie D., Sepúlveda N., Niza M. M. R. E., Tavares L. Evaluation of viremia, proviral load and cytokine profile in naturally feline immunodeficiency virus infected cats treated with two different protocols of recombinant feline interferon omega. Res. Vet. Sci., 2015, vol. 99, pp. 87–95. https://doi.org/10.1016/j.rvsc.2015.02.008
  7. Leal R. O., Gil S., Sepúlveda N., McGahie D., Duarte A., Niza M. M. R. E., Tavares L. Monitoring acute phase proteins in retrovirus infected cats undergoing feline interferon-ω therapy. J. Small Anim. Pract., 2014, vol. 55, pp. 39–45. https://doi.org/10.1111/jsap.12160
  8. Lecce J. G., Cummins J. M., Richards A. B. Treatment of rotavirus infection in neonate and weanling pigs using natural human interferon alpha. Molecular biotherapy, 1990, vol. 2, no. 4, pp. 211–216.
  9. Litzlbauer P., Weber K., Mueller R. S. Oral and subcutaneous therapy of canine atopic dermatitis with recombinant feline interferon omega. Cytokine, 2014, vol. 66, no. 1, pp. 54–59. https://doi.org/10.1016/j.cyto.2013.12.001
  10. Luo R., Fang L., Jin H., Jiang Y., Wang D., Chen H., Xiao S. Antiviral activity of type I and type III interferons against porcine reproductive and respiratory syndrome virus (PRRSV). Antiviral. Res., 2011, vol. 91, no. 2, pp. 99–101. https://doi.org/10.1016/j.antiviral.2011.04.017
  11. Mamber S. W., Lins J., Gurel V., Hutcheson D. P., Pinedo P., Bechtol D., Krakowka S., Fields-Henderson R., Cummins J. M. Low-dose oral interferon modulates expression of inflammatory and autoimmune genes in cattle. Vet. Immunol. Immunopathol., 2016, vol. 172, pp. 64–71. https://doi.org/10.1016/j.vetimm.2016.03.006
  12. Marcus P. I., van der Heide L., Sekellick M. J. Interferon action on avian viruses. I. Oral administration of chicken interferon-alpha ameliorates Newcastle disease. J. Interferon Cytokine Res., 1999, vol. 19, no. 8, pp. 881–885. https://doi.org/10.1089/107999099313406
  13. Martin V., Najbar W., Gueguen S., Grousson D., Eun H. M., Lebreux B., Aubert A. Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled challenge trial. Vet. Microbiol., 2002, vol. 89, no. 203, pp. 115–127. https://doi.org/10.1016/S0378-1135(02)00173-6
  14. Masuda Y., Matsuda A., Usui T., Sugai T., Asano A., Yamano Y. Biological effects of chicken type III interferon on expression of interferon-stimulated genes in chickens: comparison with type I and type II interferons. J. Vet. Med. Sci., 2012, vol. 74, no. 11, pp. 1381–1386. https://doi.org/10.1292/jvms.11-0517
  15. McCullough B. Interferon response in cats. Infect. Dis., 1972, vol. 125, no. 2, pp. 174–177. https://doi.org/10.1093/infdis/125.2.174
  1. Meng S., Yang L., Xu C., Qin Z., Xu H., Wang Y., Sun L., Liu W. Recombinant chicken interferon-α inhibits H9N2 avian influenza virus replication in vivo by oral administration. J. Interferon Cytokine Res., 2011, vol. 31, no. 7, pp. 533–538. https://doi.org/10.1089/jir.2010.0123
  2. Mihaljevic S. Y. First clinical experiences with omega-interferon in the treatment of chronic gingivitis-stomatitis-oropharyngitis of cats. Der Prakt. Tierarzt, 2003, vol. 84, pp. 350–361.
  3. Minagawa T., Ishiwata K., Kajimoto T. Feline interferon-omega treatment on canine parvovirus infection. Vet. Microbiol., 1999, vol. 69, no. 1–2, pp. 51–53. https://doi.org/10.1016/S0378-1135(99)00087-5
  4. Moore B. R., Krakowka S., Cummins J. M., Robertson J. T. Changes in airway inflammatory cell populations in standardbred racehorses after interferon-alpha administration. Vet. Immunol. Immunopathol., 1996, vol. 49, no. 4, pp. 347–358. https://doi.org/10.1016/0165-2427(95)05480-4
  5. Moore I., Horney B., Day K., Lofstedt J., Cribb A. E. Treatment of inflammatory airway disease in young standardbreds with interferon alpha. Can. Vet. J., 2004, vol. 45, no. 7, pp. 594–601.
  6. Moraes M. P., Chinsangaram J., Brum M. C. S., Grubman M. J. Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine. Vaccine, 2003, vol. 22, no. 2, pp. 268–279. https://doi.org/10.1016/S0264-410X(03)00560-7
  7. Moraes M. P., de los Santos T., Koster M., Turecek T., Wang H., Andreyev V. G., Grubman M. J. Enhanced antiviral activity against foot-and-mouth disease virus by a combination of type I and II porcine interferons. J. Virol., 2007, vol. 81, no. 13, pp. 7124–7135. https://doi.org/10.1128/JVI.02775-06
  8. Nagata S., Taira H., Hall A., Johnsrud L., Streuli M., Ecsodi J., Boll W., Cantell K., Weissmann C. Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature, 1980, vol. 284, no. 5754, pp. 316–320. https://doi.org/10.1038/284316a0
  9. Nagaya H., Kanaya T., Kaki H., Tobita Y., Takahashi M., Takahashi H., Yokomizo Y., Inumaru S. J. Establishment of a large-scale purification procedure for purified recombinant bovine interferon-τ produced by a silkworm-baculovirus gene expression system. J. Vet. Med. Sci., 2004, vol. 66, no. 11, pp. 1395–1401. https://doi.org/10.1292/jvms.66.1395
  10. Ohmann H. B., Lawman M. J. P., Babiuk L. A. Bovine interferon: its biology and application in veterinary medicine. Antiviral Res., 1987, vol. 7, no. 4, pp. 187–210. https://doi.org/10.1016/0166-3542(87)90028-3
  11. Oksamytnyi V. M., Kupchinsky L. G., Konovalenko V. A., Spivak M. Ya., Lazarev O. P. The intensity of incorporation of labeled lymphokines (native and modified) in animal cells (in vitro, in vivo). Proc. Sci.-Pract. Symp. “Scientific support of agriculture of Ukraine in modern terms”, Bila Tserkva, 1995, pp. 94–95. (in Ukrainian)
  12. Olivry T., DeBoer D. J., Favrot C., Jackson H. A., Mueller R. S., Nuttall T., Prélaud P. International Committee on Allergic Diseases of Animals. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet. Res., 2015, vol. 11, no. 1, p. 210. https://doi.org/10.1186/s12917-015-0514-6
  13. Ortiz A., Fuchs S. Y. Anti-metastatic functions of type 1 interferons: Foundation for the adjuvant therapy of cancer. Cytokine, 2017, vol. 89, pp. 4–11. https://doi.org/10.1016/j.cyto.2016.01.010
  14. Paltrinieri S., Crippa A., Comerio T., Angioletti A., Roccabianca P. Evaluation of Inflammation and Immunity in Cats With Spontaneous Parvovirus Infection: Consequences of Recombinant Feline Interferon-Omega Administration. Vet. Immunol. Immunopathol., 2007, vol. 118, no. 1–2, pp. 68–74. https://doi.org/10.1016/j.vetimm.2007.04.007
  15. Parkhomenko S. A., Zeynalov O. A. Feliferon efficacy in the feline panleukopenia treatment. Veterinary Medicine, 2016, no. 2, pp. 30–33. (in Russian)
  16. Parkhomenko S. A., Zeynalov O. A. The use of feliferone in the treatment of herpesviral rhinotracheitis in cats. Modern Veterinary Medicine, 2015, no. 5, pp. 28–30. (in Russian)
  17. Parkhomenko S. A., Zeynalov O. A. Therapeutic Efficacy of Feliferon in the Feline Immunodeficiency Virus. Russian veterinary journal, 2017, no. 5, pp. 34–36. (in Russian)
  1. Pedretti E., Passeri B., Amadori M., Isola P., Di Pede P., Telera A., Vescovini R., Quintavalla F., Pistello M. Low-dose interferon-alpha treatment for feline immunodeficiency virus infection. Vet. Immunol. Immunopathol.2006, vol. 109, no. 3–4, pp. 245–254. https://doi.org/10.1016/j.vetimm.2005.08.020
  2. Peel J. E., Kolly C., Siegenthaler B., Martinod S. R. Prophylactic effects of recombinant bovine interferon-alpha I1 on acute Salmonella typhimurium infection in calves. Am. J. Vet. Res., 1990, vol. 51, no. 7, pp. 1095–1099.
  3. Pei J., Sekellick M. J., Marcus P. I., Choi I. S., Collisson E. W. Chicken interferon type I inhibits infectious bronchitis virus replication and associated respiratory illness. J. Interferon Cytokine Res., 2001, vol. 21, no. 12, pp. 1071–1077. https://doi.org/10.1089/107999001317205204
  1. Perez-Martin E., Weiss M., Diaz-San Segundo F., Pacheco J. M., Arzt J., Grubman M. J., de los Santos T. Bovine type III interferon significantly delays and reduces the severity of foot-and-mouth disease in cattle. J. Virol., 2012, vol. 86, no. 8, pp. 4477–4487. https://doi.org/10.1128/JVI.06683-11
  2. Pontzer C. H., Yamamoto J. K., Bazer F. W., Ott T. L., Johnson H. M. Potent anti-feline immunodeficiency virus and antihuman immunodeficiency virus effect of IFN-τ. J. Immunol., 1997, vol. 158, no. 9, pp. 4351–4357.
  3. Reuter A., Soubies S., Härtle S., Schusser B., Kaspers B., Staeheli P., Rubbenstroth D. Antiviral Activity of Lambda Interferon in Chickens.  J. Virol., 2014, vol. 88, no. 5, pp. 2835–2843. https://doi.org/10.1128/JVI.02764-13
  4. Rogez C., Martin M., Dereuddre-Bosquet N., Martal J., Dormont D., Clayette P. Anti-human immunodeficiency virus activity of tau interferon in human macrophages: involvement of cellular factors and β-chemokines. J. Virol., 2003, vol. 77, no. 23, pp. 12914–12920. https://doi.org/10.1128/JVI.77.23.12914-12920.2003
  5. Röll S., Härtle S., Lütteke T., Kaspers B., Härtle S. Tissue and time specific expression pattern of interferon regulated genes in the chicken. BMC Genomics, 2017, vol. 18, no. 1, p. 264.
  6. Roney C. S., Rossi C. R., Smith P. C., Lauerman L. C., Spano J. S., Hanrahan L. A., William J. C. Effect of human leukocyte α-interferon on prevention of infection bovine rhinotracheitis virus infection of cattle. Am. J. Vet. Res., 1985, vol. 46, no. 6, pp. 1251–1255.
  7. Sang Y., Rowland R. R., Blecha F. Molecular characterization and antiviral analyses of porcine type III interferons. J. Interferon Cytokine Res., 2010, vol. 30, no. 11, pp. 1–7. https://doi.org/10.1089/jir.2010.0016
  8. Sang Y., Rowland R. R., Hesse R. A., Blecha F. Differential expression and activity of the porcine type I interferon family. Physiol. Genomics, 2010, vol. 42, no. 2, pp. 248–258. https://doi.org/10.1152/physiolgenomics.00198.2009
  9. Santhakumar D., Iqbal M., Nair V., Munir M. Chicken IFN Kappa: A Novel Cytokine with Antiviral Activities. Sci. Rep., 2017, vol. 7, no. 1, p. 2719. https://doi.org/10.1038/s41598-017-02951-2
  10. Santhakumar D., Rubbenstroth D., Martinez-Sobrido L., Munir M. Avian Interferons and Their Antiviral Effectors. Front. Immunol., 2017, vol. 8, p. 49. https://doi.org/10.3389/fimmu.2017.00049
  11. Schwers A., Severin J. E., Bublot M., Maenhoudt M., Pastoret P. P., Broecke C., van den Zilimwabagabo P., Velan B., Cohen S., Shafferman A., Werenne J. J. Protection of cattle from infection with vaccinia virus by bovine interferon alpha C. Vet. Rec., 1989, vol. 125, no. 1, pp. 15–16. https://doi.org/10.1136/vr.125.1.15
  12. Schwers A., Vanden Broecke C., Maenhoudt M., Beduin J. M., Werenne J., Pastoret P. P. Experimental rotavirus diarrhoea in colostrum-deprived newborn calves: assay of treatment by administration of bacterially produced human interferon (Hu-IFNα2). Ann. Rech. Vet., 1985, vol. 16, no. 3, pp. 213–218.
  13. Sedegov S. V. The experience of using the drug “Feliferon” in the complex therapy of respiratory viral infections of cats. Journal of Small Animal Practice, 2017, vol. 8, no. 2, pp. 57–59. (in Russian)
  1. Sentsui H., Takami R., Nishimori T., Murakami K., Yokoyama T., Yokomizo Y. Anti-viral effect of interferon-alpha on bovine viral diarrhea virus. J. Vet. Med. Sci., 1998, vol. 60, no. 12, pp. 1329–1333. https://doi.org/10.1292/jvms.60.1329
  2. Spivak N. Ya. Antibacterial efficiency of interferon preparations and its products in various biological systems. Dr. biol. sci. diss. Kyiv, 1987, 245 p. (in Russian)
  3. Spivak N. Ya., Belotsky S. M. Interferon — from molecules to medicines. Fiziol. J., 2007, vol. 53, no. 2, pp. 98–107. (in Russian)
  4. Spivak N. Ya., Karpov A. V., Zholobak N. M. Interferon inducers — from theory to practice. Microb. J., 2003, vol. 65, no. 1–2, pp. 191–204. (in Ukrainian)
  1. Spivak N. Ya., Smirnov V. V., Kuznetsov V. P. Effect of different interferon preparations on pathogenic microorganisms. Microb. J., 1983, vol. 45, no. 2, pp. 63–66. (in Russian)
  2. Taniguchi T., Fujii-Kuriyama Y., Muramatsu M. Molecular cloning of human interferon cDNA. Proc. Natl. Acad. Sci. USA, 1980, vol. 77, no. 7, pp. 4003–4006. https://doi.org/10.1073/pnas.77.7.4003
  3. 10th annual report of the European Medicines Agency, 2004. EMEA/61492/2005/EN/Final. EMEA, 2005.
  1. Vandenbroeck K., NauwynckH., VanderpootenA., Van Reeth K., Goddeeris B., Billiau A. Recombinant porcine IFN-γ potentiates the secondary IgG and IgA responses to an inactivated suid herpesvirus-1 vaccine and reduces postchallenge weight loss and fever in pigs. J. Interferon Cytokine Res., 2009, vol. 18, no. 9, pp. 739–744. https://doi.org/10.1089/jir.1998.18.739
  2. Weiss R. C., Cummins J. M., Richards A. B. Low-dose orally administered alpha interferon treatment for feline leukemia virus infection. J. Am. Vet. Med. Assoc., 1991, vol. 199, no. 10, pp. 1477–1481.
  3. Werenne J., Vanden Broecke C., Schwers A., Goossens A., Bugyaki L., Maenhoudt M., Pastoret P. P. Antiviral effect of bacterially produced human interferon (Hu-IFNα2) against experimental vaccinia infection in calves.J. Interferon Res., 1985, vol. 5, no. 1, pp. 129–136. https://doi.org/10.1089/jir.1985.5.129
  4. Wu Q., Brum M. C., Caron L., Koster M., Grubman M. J. Adenovirus-mediated type I interferon expression delays and reduces disease signs in cattle challenged with foot-and-mouth disease virus. J. Interferon Cytokine Res., 2003, vol. 23, no. 7, pp. 359–368. https://doi.org/10.1089/107999003322226014
  5. Xie L., Liu M., Fang L., Su X., Cai K., Wang D., Chen H., Xiao S. Molecular cloning and functional characterization of porcine stimulator of interferon genes (STING). Dev. Comp. Immunol., 2010, vol. 34, no. 8, pp. 847–854. https://doi.org/10.1016/j.dci.2010.03.005
  6. Yang L., Xu L., Li Y., Li J., Bi Y., Liu W. Molecular and Functional Characterization of Canine Interferon-Epsilon. J. Interferon Cytokine Res., 2013, vol. 33, no. 12, pp. 760–768. https://doi.org/10.1089/jir.2013.0037
  7. Yao Q., Fischer K. P., Arnesen K., Tyrrell D. L., Gutfreund K. S. Molecular cloning, expression and characterization of Pekin duck interferon-λ. Gene, 2014, vol. 548, no. 1, pp. 29–38. https://doi.org/10.1016/j.gene.2014.06.066
  8. Yasukawa K., Saito S., Kubo T., Shibasaki Y., Yamaoka K., Hachimura H., Kuyama T., Amimoto A., Kumata T., Kitahara Y., Takenaka M., Matsumura H., Uno T., Uchino T., Takehara K., Nishida K., Kadoya M., Sato M., Kato K., Matsumoto K., Saito S., Shimoda T. Low-dose recombinant canine interferon-gamma for treatment of canine atopic dermatitis: an open randomized comparative trial of two doses. Vet. Dermatol., 2010, vol. 21, no. 1, pp. 42–49. https://doi.org/10.1111/j.1365-3164.2009.00764.x
  9. Yilma T. Sensitivity of ovine choroid plexus cells to human and other animal interferons. J. Gen. Virol., 1983, vol. 64, no. 9, pp. 2013–2016. https://doi.org/10.1099/0022-1317-64-9-2013
  1. Young A. S., Maritim A. C., Kariuki D. P., Stagg D. A., Wafula J. M.,Mutugi J. J., Cummins J. M., Richards A. B., Burns C. Low-dose oral administration of human interferon alpha can control the development of Theileria parva infection in cattle. Parasitology, 1990, vol. 101, no. 2, pp. 201–209. https://doi.org/10.1017/S0031182000063241
  2. Yuk S. S., Lee D. H., Park J. K., Tseren-Ochir E. O., Kwon J. H., Noh J. Y., Lee J. B., Park S. Y., Choi I. S., Song C. S. Pre-immune state induced by chicken interferon gamma inhibits the replication of H1N1 human and H9N2 avian influenza viruses in chicken embryo fibroblasts. Virol. J., 2016, vol. 13, p. 71. https://doi.org/10.1186/s12985-016-0527-1
  3. Zhang X., Wu H., Liu C., Sun X., Zu S., Tian J., Qu L., Li S. The function of feline stimulator of interferon gene (STING) is evolutionarily conserved. Vet. Immunol. Immunopathol., 2016, vol. 169, pp. 54–62. https://doi.org/10.1016/j.vetimm.2015.12.005
  4. Zhang Z., Zou T., Hu X., Jin H. Type III interferon gene expression in response to influenza virus infection in chicken and duck embryonic fibroblasts. Mol. Immunol., 2015, vol. 68, pt. C, pp. 657–562. https://doi.org/10.1016/j.molimm.2015.10.013
  5. Zhao H., Ma J., Wang Y., Liu J., Shao Y., Li J., Jiang G., Xing M. Molecular cloning and functional characterization of eleven subtypes of interferon-α in Amur tigers (Panthera tigris altaica). Dev. Comp. Immunol., 2017, vol. 77, pp. 46–55. https://doi.org/10.1016/j.dci.2017.07.017
  6. Zhao J., Yu H.-Y., Zhang J.-L., Wang X.-M, Li J.-P., Hu Y., Wang M.-L., Shen Y.-Z., Xu J.-D., Han G.-X, Chen J. Pharmacokinetic studies of the recombinant chicken interferon-α in broiler chickens. J. Vet. Med. Sci., 2017, vol. 79, no. 2, pp. 314–319. https://doi.org/10.1292/jvms.15-0681
  7. Zhou H., Chen S., Zhou Q., Wei Y., Wang M., Jia R., Zhu D., Liu M., Liu F., Yang Q., Wu Y., Sun K., Chen X., Cheng A. Cross-Species Antiviral Activity of Goose Interferons against Duck Plague Virus Is Related to Its Positive Self-Feedback Regulation and Subsequent Interferon Stimulated Genes Induction. Viruses, 2016, vol. 8, no. 7, p. 195. https://doi.org/10.3390/v8070195

Download full text in PDF format

© 2016 Institute of Animal Biology